A Phase 2 interventional study of Paclitaxel and Bevacizumab in Non Small Cell Lung Cancer Metastatic and Interstitial Lung Disease (ILD), sponsored by Intergroupe Francophone de Cancerologie Thoracique. Not yet recruiting at 31 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Intergroupe Francophone de Cancerologie Thoracique · Phase 2, Interventional, and Treatment
How we know · 17 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Lung Diseases, Interstitial with a site in France — 37 open to participants now, 48 under way, 15 of them phase 3. Lung Diseases, Interstitial · France.
Among the 90 studies in Lung Diseases, Interstitial with a site in France, this one is the 33rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 15 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 28 of the 47 other live ones, and was the 84th registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →37 of the 90 studies in Lung Diseases, Interstitial with a site in France are open now. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18+
Boehringer Ingelheim · Sites in France, United States, Argentina and 17 more countries
Ages 18+
Boehringer Ingelheim · Sites in France, United States, Argentina and 19 more countries
Ages 2–17
Insmed Incorporated · Sites in France, United States, Czechia and 5 more countries
Ages 18+
Liquidia Technologies, Inc. · Sites in France, United States, Australia and 9 more countries
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 29
First in 2003; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 138 across the 60 interventional studies, 265 across the 30 observational. Of the 34 that completed or were terminated, 12 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 90 have an industry lead sponsor. The 10 most frequent:
Intergroupe Francophone de Cancerologie Thoracique is the lead sponsor of 57 studies on the registry; 10 are open to participants now.
Intergroupe Francophone de Cancerologie Thoracique has 1 study filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
15 of the studies in Lung Diseases, Interstitial with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06806592Phase 3Boehringer IngelheimA Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | 2027-04-15 |
| NCT05943535Phase 3United TherapeuticsStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | 2027-11 |
| NCT06235645University Hospital, ToursdEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound | 2026-11 |
| NCT06892951University Hospital, ToursCaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia | 2026-12 |
Add all 15 to your calendar (.ics) → With an account.
Among the 90 studies in Lung Diseases, Interstitial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lung cancer is a leading cause of cancer-related death worldwide. Interstitial Lung Diseases are closely associated with lung cancer either as complications or comorbidities to be considered for treatment.
Recently, a survey concerning the management of lung cancer in patients with ILDs was conducted by the Interstitial Lung Diseases and Thoracic Oncology Assemblies of the European Respiratory Society. Out of 494 practitioners, mostly pulmonologists, this survey showed that the majority of metastatic patients with pulmonary fibrosis would not be treated (69%), but that 25% and 31% of clinicians would offer chemotherapy or immunotherapy, respectively.
The systemic therapy is not clearly codified. There is a risk of worsening of ILDs with most of the treatments used in lung cancer including surgery, radiation therapy or certain systemic therapies. The Japanese Society of Pneumology has recently published proposals for care. However, the Asian population is unique in its incidence of ILDs and the frequency of drug toxicities and these recommendations may not be relevant for other populations. Thus, data are still needed to validate carboplatin and weekly paclitaxel as the best regimen for first-line treatment of NSCLC patients with ILD in a caucasian population.
In 2nd line setting, immune checkpoint blocker (ICB) in monotherapy or associated with chemotherapy has become an essential part of the therapeutic arsenal in advanced NSCLC. Several agents have been shown to be superior to docetaxel, following platinum-based chemotherapy failure, and have resulted in several marketing authorizations for PD-1 inhibitors (nivolumab, pembrolizumab) and PD-L1 inhibitors (atezolizumab).
The long-term benefits of using ICBs as a second-line therapy are now clear. Survival at 5 years is 10% higher than that obtained with docetaxel alone.
The safety profile is well known in particular with a risk of pulmonary toxicity. It should be noted that in most trials, patients with ILDs were not included. Therefore, we do not have trial data from these pivotal trials in patients with concomitant ILD.
Two prospective studies are available on the use of nivolumab in the second-line setting in patients with idiopathic ILDs. The first, in an Asian population, included 6 patients. It showed an interesting response rate of 50% without grade III or IV pulmonary toxicity or worsening of at 12 weeks.
Following this, the same team proposed a multicenter phase 2 study. Included patients had mild ILDs (VCf >80%) and were treated with nivolumab in 2nd line. The primary objective was PFS at 6 months. 18 patients were treated. 3 patients developed toxicity leading to discontinuation of nivolumab including 2 patients with grade 2 pneumonitis. PFS at 6 months was 56%, response rate was 39% and disease control achieved for 72% of patients.
In a recent prospective study in Asia, atezolizumab was administered to patients with moderate IPF and advanced NSCLC. The study was stopped prematurely due to a high incidence of inflammatory pneumonitis.
Thus, data are still needed to assess the safety of ICB in NSCLC patients with ILD in second line setting.
Inclusion Criteria for both parts:
Inclusion Criteria for part:
Exclusion criteria for both parts
Exclusion criteria specific to second line part
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carboplatine + paclitaxel + bevacizumab for up to 4 cycles
Drug: Paclitaxel · Drug: Bevacizumab · Drug: Carboplatin
Paclitaxel with or without bevacizumab or pemetred or vinorelbine (gemcitabine is possible but not recommended)
Drug: Paclitaxel · Drug: Bevacizumab · Drug: Pemetrexed · Drug: Vinorelbine · Drug: Gemcitabine
Nivolumab of pembrolizumab
Drug: Nivolumab · Drug: Pembrolizumab
Paclitaxel 90 mg/m² D1, D8, D15 Q4W
Bevacizumab 10 mg/kg D1, D15 Q4W
Carboplatin AUC D1 Q4W
Pemetrexed 500 mg/m² D1 Q3W
Vinorelbine 25 mg/m² D1, D8 Q3W
Nivolumab 240 mg D1 Q2W
Pembrolizumab 200 mg D1 Q3W
Gemcitabine 1150 mg/m² D1, D8 Q3W
1st line part: disease Control Rate at 8 weeks
Assessed by investigators according to RECIST 1.1.
Time frame: 8 weeks from date of inclusion
2nd line part: Treatment related respiratory worsening leading to discontinuation of treatment during the first 6 months
Time frame: 6 months from randomisation
Progression-free survival
Time frame: About 6 months
Duration of response
Time frame: About 6 months
Overall Survival
Time frame: About 20 months
Best overall response
Time frame: About 6 months
1st line part: Disease control rate at 8 weeks
Assessed by Independent Central Review
Time frame: 8 weeks
2nd line part: Disease control rate at 8 weeks
Assessed by Investigators
Time frame: 8 weeks
Progression-free survival according to ILDs pattern on CT scan
Time frame: About 6 months
Duration of response according to ILDs pattern on CT scan
Time frame: About 6 months
Overall Survival according to ILDs pattern on CT scan
Time frame: About 20 months
Best overall response according to ILDs pattern on CT scan
Time frame: About 6 months
Progression-free survival according to ILDs severity (FVC/DLCO)
Time frame: About 6 months
Duration of response according to ILDs severity (FVC/DLCO)
Time frame: About 6 months
Overall Survival according to ILDs severity (FVC/DLCO)
Time frame: About 20 months
Best overall response according to ILDs severity (FVC/DLCO)
Time frame: About 6 months
Respiratory evolution (number of exaxerbations of ILD) with or without anti-fibrosing treatment
Time frame: About 6 months
Progression-free survival with or without anti-fibrosing treatment
Time frame: About 6 months
Duration of response with or without anti-fibrosing treatment
Time frame: About 6 months
Overall Survival with or without anti-fibrosing treatment
Time frame: About 20 months
Best overall response with or without anti-fibrosing treatment
Time frame: About 6 months
Overall health status assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire
Time frame: About 6 months
Incidence, nature, and severity of adverse events
Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 6.0
Time frame: About 6 months
2nd ine part: Incidence, nature, and severity of immune related adverse events
Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 6.0
Time frame: About 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Aug 2028, 23 months later.
Of 53 phase 2 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 71. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paclitaxel · Bevacizumab · Carboplatin · Nivolumab · Pembrolizumab
Intergroupe Francophone de Cancerologie Thoracique